000166641 001__ 166641
000166641 005__ 20240229133526.0
000166641 0247_ $$2doi$$a10.1016/j.cellimm.2020.104274
000166641 0247_ $$2pmid$$apmid:33383383
000166641 0247_ $$2ISSN$$a0008-8749
000166641 0247_ $$2ISSN$$a1090-2163
000166641 0247_ $$2altmetric$$aaltmetric:96831647
000166641 037__ $$aDKFZ-2021-00008
000166641 041__ $$aeng
000166641 082__ $$a610
000166641 1001_ $$0P:(DE-He78)d239d6a28875058b40c13266babadb58$$aGebhardt, Christoffer$$b0$$eFirst author
000166641 245__ $$aPotential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study.
000166641 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2021
000166641 3367_ $$2DRIVER$$aarticle
000166641 3367_ $$2DataCite$$aOutput Types/Journal article
000166641 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1609840039_26094
000166641 3367_ $$2BibTeX$$aARTICLE
000166641 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166641 3367_ $$00$$2EndNote$$aJournal Article
000166641 500__ $$aVolume 360, February 2021, 104274#EA:A370#LA:A370#
000166641 520__ $$aThe low dose application of chemotherapeutic agents such as paclitaxel was previously shown to initiate anti-tumor activity by neutralizing myeloid-derived suppressor cells (MDSCs) in melanoma mouse models. Here, we investigated immunomodulating effects of low-dose paclitaxel in 9 metastatic melanoma patients resistant to prior treatments. Three patients showed response to therapy (two partial responses and one stable disease). In responding patients, paclitaxel decreased the frequency and immunosuppressive pattern of MDSCs in the peripheral blood and skin metastases. Furthermore, paclitaxel modulated levels of inflammatory mediators in the serum. In addition, responders displayed enhanced frequencies of tumor-infiltrating CD8+ T cells and their activity indicated by the upregulation of CD25 and TCR ζ-chain expression. Our study suggests that low-dose paclitaxel treatment could improve clinical outcome of some advanced melanoma patients by enhancing anti-tumor immunity and might be proposed for combined melanoma immunotherapy.
000166641 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000166641 588__ $$aDataset connected to CrossRef, PubMed,
000166641 650_7 $$2Other$$aImmune checkpoint blockade
000166641 650_7 $$2Other$$aImmunotherapy
000166641 650_7 $$2Other$$aMelanoma
000166641 650_7 $$2Other$$aMyeloid suppressor cells
000166641 650_7 $$2Other$$aPaclitaxel
000166641 7001_ $$0P:(DE-HGF)0$$aSimon, Sonja C S$$b1
000166641 7001_ $$0P:(DE-He78)d56d42ddfa25c8d79cba10aed608b0df$$aWeber, Rebekka$$b2$$udkfz
000166641 7001_ $$0P:(DE-HGF)0$$aGries, Mirko$$b3
000166641 7001_ $$0P:(DE-HGF)0$$aMun, Dong Hun$$b4
000166641 7001_ $$aReinhard, Raphael$$b5
000166641 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b6$$udkfz
000166641 7001_ $$0P:(DE-He78)38be34240daf8b47325afc7910e77f7b$$aUmansky, Viktor$$b7$$udkfz
000166641 7001_ $$0P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aUtikal, Jochen$$b8$$eLast author$$udkfz
000166641 773__ $$0PERI:(DE-600)1462601-9$$a10.1016/j.cellimm.2020.104274$$gVol. 360, p. 104274 -$$p104274$$tCellular immunology$$v360$$x0008-8749$$y2021
000166641 909CO $$ooai:inrepo02.dkfz.de:166641$$pVDB
000166641 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d239d6a28875058b40c13266babadb58$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000166641 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000166641 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d56d42ddfa25c8d79cba10aed608b0df$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000166641 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000166641 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000166641 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000166641 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)38be34240daf8b47325afc7910e77f7b$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000166641 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000166641 9130_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000166641 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000166641 9141_ $$y2021
000166641 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-09-09$$wger
000166641 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-09
000166641 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-09
000166641 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-09
000166641 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-09-09
000166641 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-09
000166641 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-09-09
000166641 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-09-09
000166641 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-09
000166641 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-09
000166641 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELL IMMUNOL : 2018$$d2020-09-09
000166641 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-09-09
000166641 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-09-09
000166641 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-09-09
000166641 9201_ $$0I:(DE-He78)A370-20160331$$kA370$$lKKE Dermatoonkologie$$x0
000166641 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000166641 980__ $$ajournal
000166641 980__ $$aVDB
000166641 980__ $$aI:(DE-He78)A370-20160331
000166641 980__ $$aI:(DE-He78)C060-20160331
000166641 980__ $$aUNRESTRICTED